The consumer’s group Public Citizen demanded the Office of the Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) conduct an investigation into “inappropriate collaboration” between the U.S. Food and Drug Administration (FDA) and Biogen over the company’s submission for Alzheimer’s drug aducanumab.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,